A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants with Early AD

Phase 3

Not yet recruiting

• Conditions: Early Alzheimers Disease
• Interventions: Drug: buntanetap/posiphen; Drug: Placebo

• Registration Number: NCT06709014
• Lead Sponsor: Annovis Bio Inc.

Brief Summary

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:

* Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?

* Does buntanetap/Posiphen improve function as measured by ADCS-iADL?

* What medical issues do participants have, if any, when taking buntanetap/Posiphen?

Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.

Participants will:

* Take buntanetap/Posiphen or a placebo every day for 18 months

* Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18

* Complete pre- and post-clinic visit phone calls

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-11-26
• Study First Submitted QC: 2024-11-26
• Study First Posted: 2024-11-29
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-09
• Last Update Posted: 2024-12-12
• Study Start: 2025-01
• Primary Completion: 2027-12
• Study Completion: 2028-06

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 760

Inclusion Criteria

1. Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.

2. Male or female, aged 55 - 85 years.

3. MMSE 21-28 at screening and baseline.

4. CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.

5. Positive for amyloid beta as defined by plasma p-tau217 level at screening.

6. Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.

7. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.

8. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

   • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

   • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

   • Intrauterine device (IUD),

   • Intrauterine hormone-releasing system (IUS),

   • Bilateral tubal occlusion,

   • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),

   • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

     • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

9. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

   • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
   • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
   • IUD,
   • IUS,
   • Bilateral tubal occlusion.

10. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent.

11. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.

12. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.

    • Cholinesterase inhibitors and/or memantine medication,
    • Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
    • Mood-stabilizing psychotropic agents including, but not limited to, lithium.

13. Adequate visual and hearing ability (physical ability to perform all the study assessments).

14. Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.

Read More

Exclusion Criteria

1. Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.

3. History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).

5. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.

6. Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

7. Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.

8. Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <60 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).

9. Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.

10. Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

11. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

12. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.

13. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

14. Participants with learning disability or developmental delay.

15. Participants whom the PI deems to be otherwise ineligible.

16. Participants with a known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified Microcrystalline Cellulose
    • Dibasic Calcium Phosphate Dihydrate
    • Mannitol
    • Stearic Acid
    • Hypromellosee (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)

17. Participant is currently pregnant, breast-feeding, and/or lactating.

18. Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.

19. Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
buntanetap	buntanetap/posiphen	-
Placebo	Placebo	-

Primary Outcome Measures

Name	Time	Method
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)	From screening to 6-month readout, to end of treatment at 18 months.	ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)	From screening to 6-month readout, to end of treatment at 18 months.	The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function.

Secondary Outcome Measures

Name	Time	Method
Volumetric MRI (hippocampus and whole brain)	At enrollment and the 6-month and 18-month visits.	Volumetric MRI (vMRI) of the brain will be assessed and compared to evaluate the loss of brain volume that occurs in AD participants.
Clinical Global Impression - Severity (CGI-S) Scale	From screening to 6-month readout, to end of treatment at 18 months.	CGI-S is a clinician-rated tool that assesses the severity of a patient's illness. It is a 7-point scale that ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill participants) for observed and reported symptoms, behavior, and function.
Clinical Dementia Rating (CDR)	From screening to 6-month readout, to end of treatment at 18 months.	The CDR Scale stages dementia, including AD, in elderly participants. The CDR uses a 3-point scale to characterize 6 domains of cognitive and functional performance, including memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care. This scale produces 2 scores, a global CDR score and a sum of boxes score (CDR-SB). The CDR-SB score ranges from 0-18 with higher scores representing more severe dementia.; CDR global score will be used for inclusion criteria. CDR sum of boxes will be used from baseline to the end of treatment.
Mini Mental State Examination Score (MMSE)	From screening to 6-month readout, to end of treatment at 18 months.	MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures). Total score ranges from 0 to 30 with a lower score indicating greater disease severity.